SEC Form 4 · accession 0001638599-17-000786
AYTU BIOPHARMA, INC · AYTU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jarrett Disbrow
Officer — Chief Operating Officer · Director
Period of report
Aug 15, 2017
Accepted (ET)
Aug 22, 2017 · 7:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385818
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 15, 2017 | A | 1,666,667 | $0.15 | A | 2,267,671 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common Stock | $0.18 | Aug 15, 2017 | A | 2,500,000 | A | Aug 15, 2017 | Aug 15, 2022 | Common Stock | 2,500,000 | 0 | D |
| Employee Stock Option GrantF2 | $3.23 | Mar 16, 2017 | D | 50,000 | D | — | Nov 11, 2025 | Common Stock | 50,000 | 0 | D |
| Employee Stock Option GrantF3 | $3.23 | Mar 16, 2017 | D | 60,000 | D | — | Jul 7, 2026 | Common Stock | 60,000 | 0 | D |
| Employee Stock Option GrantF2 | $0.82 | Mar 16, 2017 | A | 50,000 | A | — | Nov 11, 2025 | Common Stock | 50,000 | 50,000 | D |
| Employee Stock Option GrantF3 | $0.82 | Mar 16, 2017 | A | 60,000 | A | — | Jul 7, 2026 | Common Stock | 60,000 | 60,000 | D |
| Warrant to Purchase Common Stock | $1.86 | holding | — | — | — | Nov 2, 2017 | Nov 2, 2021 | Common Stock | 166,666 | 0 | D |
| Warrant to Purchase Common Stock | $6.00 | holding | — | — | — | May 6, 2016 | May 6, 2021 | Common Stock | 20,834 | 0 | D |
Explanation of responses
- F1Of these shares, 165,000 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations.
- F233.3% vest on November 11, 2016, 33.3% vest on November 11, 2017 and 33.3% vest on November 11, 2018, subject to the Grantee's continued service as an employee on such dates.
- F333.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's continued service as an employee on such dates.
- F4These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option.